<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01755949</url>
  </required_header>
  <id_info>
    <org_study_id>12-001686</org_study_id>
    <nct_id>NCT01755949</nct_id>
  </id_info>
  <brief_title>Colchicine and CRP in Atrial Fibrillation and AF Ablation</brief_title>
  <official_title>Impact and Time Course of Colchicine Therapy on C-reactive Protein Elevation in Chronic Atrial Fibrillation (AF) and Post AF Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Colchicine will lower C-reactive protein (CRP) in chronic atrial fibrillation and reduce the
      rise in CRP which occurs following atrial fibrillation ablation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Three groups of patients will be randomized to colchicine 0.6 mg PO BID or matching placebo:

        1. Paroxysmal atrial fibrillation, pre-ablation

        2. Persistent atrial fibrillation, pre-ablation

        3. Chronic persistent atrial fibrillation
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>one month</time_frame>
    <description>Three groups of atrial fibrillation patients, 20 per group, will be randomized to receive colchicine or matching placebo for one month, and have intensive monitoring of c-reactive protein during the month.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sinus rhythm on ECG</measure>
    <time_frame>One month</time_frame>
    <description>All patients will have 12 lead ECG obtained one month after study enrollment</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Chronic atrial fibrillation, colchicine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Colchicine 0.6 mg PO BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic atrial fibrillation, placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching lacebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-ablation, sinus rhythm, colchicine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Colchicine 0.6 mg PO BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-ablation, sinus rhythm, placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-ablation, AF, colchicine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Colchicine 0.6 mg PO BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-ablation, AF, placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine, 0.6 mg PO BID</intervention_name>
    <description>Colchicine tablets will be over-encapsulated by the research pharmacy to be indistinguishable from placebo</description>
    <arm_group_label>Chronic atrial fibrillation, colchicine</arm_group_label>
    <arm_group_label>Pre-ablation, sinus rhythm, colchicine</arm_group_label>
    <arm_group_label>Pre-ablation, AF, colchicine</arm_group_label>
    <other_name>Colcrys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo</intervention_name>
    <description>Matching placebo tablets will be encapsulated by the research pharmacy to be indistinguishable from active drug</description>
    <arm_group_label>Chronic atrial fibrillation, placebo</arm_group_label>
    <arm_group_label>Pre-ablation, sinus rhythm, placebo</arm_group_label>
    <arm_group_label>Pre-ablation, AF, placebo</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Group 1: Persistent or chronic AF presenting for evaluation in cardiology offices.
             Diagnosis of AF will be made based on the 12 -lead surface ECG.

          -  Group 2: Paroxysmal AF scheduled to go AF ablation presenting to the electrophysiology
             laboratory for the procedure in sinus rhythm..

          -  Group 3:Chronic AF scheduled to go clinically indicated AF ablation, and presenting in
             the electrophysiology laboratory in atrial fibrillation .

        Exclusion Criteria:

          1. Abnormal liver function with elevated enzymes&gt; 1.5 times the normal.

          2. Abnormal kidney function with glomerular filtration rate &lt; 50 ml/min

          3. Increased levels of creatine kinase or known myopathy

          4. Neutropenia

          5. Known GI disorders

          6. Women of childbearing age who have not had surgical sterilization and are not using
             oral contraceptives, or who's spouse has not had surgical sterilization will be
             excluded due to the length of the trial and the possibility that they could become
             pregnant after entry.

          7. Pregnant and lactating women

          8. Lactose intolerance

          9. Known sensitivity, allergy, or contraindication to colchicine use -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph L. Blackshear, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Consultant in Cardiovascular Diseases</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dana G. Kontras, RN</last_name>
    <phone>904 953-8577</phone>
    <email>kontras.dana@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana g. Kontras, RN</last_name>
      <phone>904-953-8577</phone>
      <email>kontras.dana@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2012</study_first_submitted>
  <study_first_submitted_qc>December 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2012</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Joseph L. Blackshear</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>catheter ablation</keyword>
  <keyword>colchicine</keyword>
  <keyword>c reactive protein</keyword>
  <keyword>CRP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 12, 2018</submitted>
    <returned>February 6, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

